Table 2

Best radiographic response for patients with mRCC and brain metastasis treated with ipilimumab and nivolumab among all patients, those treated in the first line setting and those treated in the second line or later setting

VariableAll patients (n=19)First line (n=13)Second line or later (n=6)
Best overall response, no. (%)
 Complete response000
 Partial response8 (42)5 (38.5)3 (50)
 Stable disease6 (32)5 (38.5)1 (17)
 Progressive disease4 (21)2 (15)2 (33)
 Not evaluable1 (5)1 (8)0
  • mRCC, metastatic renal cell carcinoma.